市場調查報告書
商品編碼
1408675
美國深奧測試市場規模和預測、區域佔有率、趨勢和成長機會分析報告範圍:按類型、技術和最終用戶US Esoteric Testing Market Size and Forecasts, Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Type, Technology, and End User |
美國深奧測試市場預計將從2022年的103.82億美元成長到2030年的312.74億美元;預計 2022 年至 2030 年CAGR為 14.8%。該報告強調了市場的普遍趨勢以及推動市場成長的因素。市場成長歸因於慢性病盛行率的上升以及人們對早期發現醫療狀況的意識不斷增強,這推動了美國深奧檢測市場的規模和成長。此外,監管機構在基因檢測和罕見疾病相關措施方面的進步可能會成為預測期內市場的重要趨勢。然而,缺乏熟練人員和高昂的程序成本阻礙了 2022-2030 年預測期內的市場成長。
早期發現醫療狀況的意識不斷增強,將推動預測期內的市場發展。
疾病的早期診斷有助於醫療專業人員和患者在護理、支持需求以及財務和法律事務方面做出各種重要的醫療決定。在註意到與特定醫療狀況相關的認知症狀後獲得準確和早期的診斷,可以在症狀惡化之前逆轉症狀,從而對患者進行有效和早期的治療。它還為醫療保健專業人員提供了充足的時間來做出更好的決策。實驗室檢查程序廣泛用於診斷與醫學專業相關的疾病,例如神經系統疾病、遺傳疾病、癌症和內分泌疾病。深奧的測試和基因測試用於診斷糖尿病、心血管疾病、血脂紊亂、癌症和遺傳疾病。
各政府監管機構也在採取措施並開展活動來促進早期診斷實踐。國家罕見疾病組織旨在透過教育、研究、宣傳和患者服務等眾多支持項目來識別、診斷和治療罕見疾病。紐約州罕見疾病工作小組是根據紐約州通過的立法(《公共衛生法》第 27-L 條)而成立的,旨在確定可以提高對罕見疾病認知的最佳實踐。透過這些舉措,可能患有罕見疾病的人可以被轉介給專家,並可以解決治療的障礙,包括經濟挑戰。這些旨在建立有關複雜遺傳和非遺傳罕見疾病的可用診斷方案的知識的舉措有利於美國深奧檢測市場的成長。
報告細分和範圍 -
「美國深奧測試市場」根據類型、技術和最終用戶進行細分。依類型,市場分為傳染病檢測、內分泌檢測、腫瘤檢測、毒理學檢測、免疫學檢測、神經學檢測等。從技術上來看,美國深奧檢測市場分為化學發光免疫分析、酵素連結免疫吸附分析、質譜分析、即時PCR、DNA定序、流式細胞儀等。就最終用戶而言,市場分為醫院和實驗室以及獨立和參考實驗室。
美國深奧檢測市場依類型分為傳染病檢測、內分泌檢測、腫瘤學檢測、毒理檢測、免疫學檢測、神經學檢測等。腫瘤檢測領域在 2022 年佔據最大的市場佔有率。傳染病檢測領域預計 2022 年至 2030 年CAGR最高。
根據技術,美國深奧檢測市場分為化學發光免疫分析、酵素連結免疫吸附分析、質譜分析、即時PCR、DNA定序、流式細胞儀等。化學發光免疫分析領域在 2022 年佔據最大的市場佔有率。酵素連結免疫吸附分析領域預計在 2022 年至 2030 年期間CAGR最高,達到 18.7%。
根據最終用戶,美國深奧檢測市場分為醫院和實驗室,以及獨立和參考實驗室。 2022 年,醫院和實驗室領域佔據了更大的市場佔有率。預計 2022 年至 2030 年複合CAGR將達到 15.2%。
深奧測試通常用於分析常規測試中未得出結論的稀有和獨特物質。為了進行這些測試,臨床實驗室需要相關專業的專業知識。因此,大型商業實驗室將這些複雜的測試外包給參考和深奧的測試實驗室。在美國進行深奧測試的一些實驗室包括 Quest Diagnostics Incorporated、Mayo Medical Laboratories、ARUP Laboratories、Myriad Genetics、Genomic Health、Foundation Medicine 和 Laboratory Corporation of America。該地區能夠進行這些專業測試的實驗室數量正在增加。
根據內分泌學會 2022 年 1 月發表的一篇文章,性腺功能減退症是男性人群中的常見病症,在老年男性、肥胖男性和 2 型糖尿病男性中患病率較高。據估計,45 歲以上男性中 35% 以及患有第 2 型糖尿病或肥胖症的男性中 30-50% 患有性腺功能減退症。此外,根據美國人口普查局的估計,65歲及以上男性性腺功能減退症的發生率從2000年的約3500萬增至2020年的約5500萬。此外,預計到2050年將增至約8700萬。這種疾病的盛行率激增是由於美國老年人口的增加。
對深奧檢測的需求激增也歸因於肝硬化病例的增加。根據 Statista 的數據,2020 年美國有 51,642 名成年人死於肝病。慢性肝病/肝硬化是 2020 年美國第 12 大死因;酒精性肝硬化發生率的增加是這種疾病的主要危險因子。
此外,合作和夥伴關係也有望推動美國深奧測試的市場成長。例如,根據美國國立衛生研究院(NIH) 2021 年10 月的新聞稿,NIH、美國食品和藥物管理局、10 家製藥公司和5 家非營利組織已聯合起來,加快針對30 名患者的基因療法的開發。數百萬美國人患有罕見疾病。儘管有近 7,000 種罕見疾病,但目前只有 2 種遺傳性疾病擁有 FDA 批准的基因療法。最近成立的客製化基因治療聯盟 (BGTC) 是 NIH 加速藥物合作夥伴 (AMP) 計劃的一部分,由 NIH 基金會牽頭,旨在加強和簡化基因治療的開發流程,以支持未滿足的醫療需求患有罕見疾病的人。
因此,性腺功能減退症、肝硬化和其他此類疾病的病例不斷增加,正在推動美國深奧檢測市場的成長。
美國深奧測試市場的公司採用各種有機和無機策略。有機策略主要包括產品發布和產品批准。此外,市場上出現的無機成長策略包括收購、合作和夥伴關係。這些成長策略使市場參與者能夠擴大業務並增強其地理影響力,從而促進整體市場的成長。此外,收購和合作策略有助於市場參與者加強其客戶群並擴大其產品組合。以下列出了美國深奧測試市場主要參與者的一些重大進展。
美國心臟協會、美國甲狀腺協會、美國食品藥物管理局 (FDA)、MyBioSource.com.、內分泌學會、美國國立衛生研究院 (NIH) 是在準備過程中參考的一些主要主要和次要來源關於美國Esoteric 測試市場的報告。
The US Esoteric Testing market is expected to grow from US$ 10.382 billion in 2022 to US$ 31.274 billion by 2030; it is estimated to grow at a CAGR of 14.8% from 2022 to 2030. The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the rising prevalence of chronic diseases and growing awareness of early detection of medical conditions, which are driving the US's esoteric testing market size and growth. Additionally, advancements in genetic testing and rare disease-related initiatives by regulatory authorities are likely to emerge as a significant trend in the market during the forecast period. However, the lack of skilled personnel and the high cost of procedure hinder market growth during the forecast period 2022-2030.
Growing Awareness of Early Detection of Medical Conditions drives the market in the forecast period.
The early diagnosis of diseases helps medical professionals and patients to make various important medical decisions in terms of care, support needs, and financial and legal matters. Obtaining accurate and early diagnosis after noticing cognitive symptoms related to a specific medical condition results in the reversal of symptoms before they are aggravated, followed by an effective and early treatment of patients. It also provides healthcare professionals sufficient time for better decision-making. Laboratory examination procedures are widely performed for the diagnosis of diseases associated with medical specialties, such as neurological disorders, genetic diseases, cancer, and endocrinological disorders. Esoteric testing and genetic testing are performed for the diagnosis of diabetes, cardiovascular disease, lipid disorders, cancer, and genetic diseases.
Various government regulatory bodies are also taking initiatives and conducting campaigns to promote early diagnosis practices. The National Organization for Rare Disorders aims to identify, diagnose, and treat rare disorders through numerous supportive programs, including education, research, advocacy, and patient services. The New York State Rare Disease Workgroup, created in response to legislation passed in New York State (Article 27-L of the Public Health Law), aims to identify best practices that could enhance the awareness of rare diseases. Through such initiatives, people potentially having rare diseases can be referred to specialists, and barriers to their treatments, including financial challenges, can be addressed. Such initiatives to build knowledge regarding available diagnosis options for complex genetic and non-genetic rare disorders favor the growth of the US esoteric testing market.
Report Segmentation and Scope -
The "US Esoteric Testing market" is segmented on the basis of type, technology, and end user. Based on type, the market is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, immunology testing, neurology testing, and others. In terms of technology, the US esoteric testing market is divided into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA sequencing, flow cytometry, and others. In terms of end users, the market is categorized into hospitals and laboratories and independent and reference laboratories.
The US esoteric testing market, by type, is segmented into infectious disease testing, endocrinology testing, oncology testing, toxicology testing, immunology testing, neurology testing, and others. The oncology testing segment held the largest market share in 2022. The infectious disease testing segment is anticipated to register the highest CAGR from 2022 to 2030.
Based on technology, the US esoteric testing market is segmented into chemiluminescence immunoassay, enzyme-linked immunosorbent assay, mass spectrometry, real-time PCR, DNA sequencing, flow cytometry, and others. The chemiluminescence immunoassay segment held the largest market share in 2022. The enzyme-linked immunosorbent assay segment is anticipated to register the highest CAGR of 18.7% during 2022-2030.
Based on end users, the US esoteric testing market is segmented into hospitals and laboratories, as well as independent and reference laboratories. The hospitals and laboratories segment held a larger share of the market in 2022. It is further expected to register a higher CAGR of 15.2% during 2022-2030.
Esoteric tests are generally performed for the analysis of rare and unique substances that are not concluded in regular tests. To perform these tests, clinical laboratories require expertise in relevant specialties. Therefore, large commercial laboratories outsource these complex tests to reference and esoteric testing laboratories. A few of the labs performing esoteric testing in the US include Quest Diagnostics Incorporated, Mayo Medical Laboratories, ARUP Laboratories, Myriad Genetics, Genomic Health, Foundation Medicine, and Laboratory Corporation of America. The number of laboratories that can perform these specialized tests is increasing in the region.
As per an article by the Endocrine Society, published in January 2022, hypogonadism is a common condition in the male population, with a higher prevalence in older men, obese men, and men with type 2 diabetes. 35% of men older than 45 years of age and 30-50% of men with type 2 diabetes or obesity are estimated to have hypogonadism. Moreover, as per the US Census Bureau's estimation, the incidences of hypogonadism in men aged 65 years and more grew from ~35 million in 2000 to ~55 million by 2020. Further, it is estimated to rise to ~87 million by 2050. The surging prevalence of this condition is due to the rise in the geriatric population in the US.
An upsurge in the demand for esoteric testing is also attributed to the rising cases of hepatic cirrhosis. As per Statista, 51,642 adults in the US died from liver disease in 2020. Chronic liver disease/cirrhosis was the 12th leading cause of mortality in the US in 2020; an increase in the incidences of alcoholic cirrhosis is a major risk factor for this disease.
Furthermore, collaborations and partnerships are also expected to propel the market growth of esoteric testing in the US. For instance, as per The National Institutes of Health (NIH) press release of October 2021, NIH, the US Food and Drug Administration, ten pharmaceutical companies, and five non-profit organizations have joined to fasten the development of gene therapies for the 30 million Americans who suffer from rare diseases. Whereas there are nearly 7,000 rare diseases, currently, only 2 heritable diseases have FDA-approved gene therapies. The recently launched Bespoke Gene Therapy Consortium (BGTC), a section of the NIH Accelerating Medicines Partnership (AMP) program and project-lead by the Foundation of NIH, aims to enhance and streamline the development process of gene therapy to support the unmet medical needs of people with rare diseases.
Thus, the burgeoning cases of hypogonadism, hepatic cirrhosis, and other such disease is driving the growth of the esoteric testing market in the US.
Companies in the US's esoteric testing market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the US's esoteric testing market are listed below.
The American Heart Association, The American Thyroid Association, The United States Food and Drug Administration (FDA), MyBioSource.com., The Endocrine Society National Institutes of Health (NIH) are a few of the major primary and secondary sources referred to while preparing the report on the US Esoteric Testing market.